GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia

Findings from the ENABLE clinical trials, which evaluated the ability of eltrombopag to raise and maintain platelet levels in patients with chronic hepatitis C virus (HCV) infection and low platelet levels that would preclude initiation of interferon-based antiviral therapy, were presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco. Use of eltrombopag to treat thrombocytopenia in patients with chronic HCV infection is not approved anywhere in the world...

Read the full story >>

More pharmaceutical & life science news:

		Daiichi Sankyo Brasil and Kyorin Pharmaceutical reach agreement in Brazil Basic agreement reached for activities in Brazil related to the development and marketing of Imidafenacin...

		AstraZeneca and Targacept announce first top-line Phase III results for TC-5214 as an adjunct treatment in patients with major depressive disorder AstraZeneca and Targacept, Inc. have announced top-line results from the first of four RENAISSANCE Phase III studies investigating the efficacy and tolerability of TC-5214...

		Novartis Phase III study shows ACZ885 helped substantially reduce steroid use in 45% of patients with serious form of childhood arthritis New pivotal Phase III data announced...

		Pfizer to present clinical data from its hematology portfolio Investigator research on several pfizer compounds to be presented...

		FDA approves ERBITUX® (cetuximab) for first-line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil ERBITUX now approved for five indications across two tumor types...

		Abbott presents HUMIRA® (adalimumab) Phase 3 study results In ABILITY-1 Study Presented at ACR, More than Twice as Many Patients Treated with HUMIRA Met Primary Endpoint Compared to Placebo...

		Interim data for Merck’s VICTRELIS™ (boceprevir) in prior null responder patients with Chronic Hepatitis C genotype 1 to be presented Merck has announced results of an interim analysis from the PROVIDE study...

		Treatment with Enbrel® (etanercept) shows significant and sustained clinical benefits in Rheumatoid Arthritis (RA) patients with moderately active disease Amgen and Pfizer Inc. have announced results of the second and final period of the PRESERVE trial...

		Positive five-year data showing effect of Viread(R) on liver fibrosis and cirrhosis caused by Chronic Hepatitis B New long-term data show no development of resistance...

Events, conferences & exhibitions:

Preparation, Labelling and Packaging of Clinical Trial Supplies
21 - 23 November 2011, London, UK

10th Annual World Drug Manufacturing Summit
29 November - 1 December 2011, Berlin, Germany

IFPAC 2012
22 - 25 January 2012 Baltimore, USA

10th Annual World Drug Manufacturing Summit
29 November - 1 December 2011, Berlin, Germany

Analytical Method Validation for Biologics, Biopharmaceuticals and Other Therapeutic Products
1 - 2 December 2011, Dublin, Ireland

Stability Programs for Product Shelf Life – From Development to Approval
5 - 6 December 2011, Berlin, Germany

Active Pharmaceutical Ingredients (API) and Drug Product Specifications
7 - 9 December 2011, Berlin, Germany

Pharmaceutical Expo 2011
16 - 18 December 2011, Bangalore, India